# Yale and McGill Collaborate to Expand Cannabis Research > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/academic-partnerships-cannabis-research/ > **Published:** 2026-03-21T15:14:16-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:42:27-04:00 > **Clinical Summary:** Explore how academic partnerships cannabis research is expanding through Yale and McGill collaboration, advancing clinical cannabis studies. --- ✦ New CED Clinical Relevance  #78Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic ResearchClinical EvidenceAcademic Medicine[Drug Development](https://cedclinic.com/hydrogen-sulfide-releasing-nsaid-derivative/)Cannabis Science Why This Matters Academic partnerships between Yale and McGill represent a significant expansion of rigorous [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) infrastructure. This collaboration may accelerate the development of evidence-based clinical protocols and standardized treatment approaches that practicing clinicians desperately need. Clinical Summary Yale University and McGill University have announced a research collaboration focused on expanding cannabis studies, though specific research priorities and methodologies have not been detailed in available reports. Both institutions have established [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) programs, with Yale’s focus on [neurobiological mechanisms](https://cedclinic.com/cannabis-tolerance-behavioral-models/) and McGill’s strengths in clinical pharmacology. The partnership suggests an intention to leverage complementary expertise across institutions to advance the scientific understanding of cannabis therapeutics. Dr. Caplan’s Take “More high-quality research partnerships like this are exactly what we need to move beyond the current patchwork of small studies and anecdotal reports. The real test will be whether they tackle the fundamental questions about dosing, drug interactions, and patient selection that we face in clinical practice every day.” Clinical Perspective 🧠 Clinicians should monitor publications emerging from this collaboration for evidence that may inform clinical decision-making. Academic partnerships often produce more robust study designs and larger patient populations than single-institution efforts. However, translation from research findings to clinical practice typically requires 3-5 years, so immediate changes to patient care protocols are not anticipated. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Yale%20and%20McGill%20Collaborate%20to%20Expand%20Cannabis%20Research%20%40drcaplan&url=https%3A//www.cannabisequipmentnews.com/news/news/22963116/yale-and-mcgill-collaborate-to-expand-cannabis-research)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.cannabisequipmentnews.com/news/news/22963116/yale-and-mcgill-collaborate-to-expand-cannabis-research)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Yale%20and%20McGill%20Collaborate%20to%20Expand%20Cannabis%20Research%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.cannabisequipmentnews.com/news/news/22963116/yale-and-mcgill-collaborate-to-expand-cannabis-research)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.cannabisequipmentnews.com/news/news/22963116/yale-and-mcgill-collaborate-to-expand-cannabis-research](https://www.cannabisequipmentnews.com/news/news/22963116/yale-and-mcgill-collaborate-to-expand-cannabis-research) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating for this cannabis research?](#What_is_the_clinical_relevance_rating_for_this_cannabis_research) - [What type of cannabis-related content does this article cover?](#What_type_of_cannabis-related_content_does_this_article_cover) - [Why is this research considered noteworthy for healthcare professionals?](#Why_is_this_research_considered_noteworthy_for_healthcare_professionals) - [What categories does this cannabis research fall under?](#What_categories_does_this_cannabis_research_fall_under) - [How should clinicians interpret the CED relevance rating system?](#How_should_clinicians_interpret_the_CED_relevance_rating_system) - [Related](#Related) ## FAQ #### What is the clinical relevance rating for this cannabis research? This article has received a CED Clinical Relevance rating of #78, indicating “Notable Clinical Interest.” This classification means the findings represent emerging research or policy developments that clinicians should monitor closely. #### What type of cannabis-related content does this article cover? This article focuses on cannabis research with clinical evidence components. It appears to be part of academic medicine coverage related to [drug development](https://cedclinic.com/hydrogen-sulfide-releasing-nsaid-derivative/) in the cannabis field. #### Why is this research considered noteworthy for healthcare professionals? The “Notable Clinical Interest” designation suggests this research presents emerging findings that could impact clinical practice. Healthcare professionals should stay informed about these developments as they may influence future treatment protocols. #### What categories does this cannabis research fall under? The research spans multiple categories including clinical evidence, academic medicine, and drug development. This interdisciplinary approach indicates comprehensive research with potential therapeutic applications. #### How should clinicians interpret the CED relevance rating system? The CED Clinical Relevance rating helps prioritize [medical cannabis research](https://cedclinic.com/cannabis-varieties-differentiation-cannabinomics/) for busy healthcare professionals. A rating of #78 with “Notable Clinical Interest” means this research merits attention but may not require immediate clinical action. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Yale and McGill Collaborate to Expand Cannabis Research”, “url”: “https://www.cannabisequipmentnews.com/news/news/22963116/yale-and-mcgill-collaborate-to-expand-cannabis-research”, “datePublished”: “2026-03-21T06:55:32Z”, “about”: “yale mcgill collaborate expand cannabis research”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence Who is putting in the work for cannabis research? – YouTube Discover key contributors advancing cannabis research and their impact on clinical studies. Watch Now [Does Cannabis Legalization Spur More Innovation Than Medical Research?](https://cedclinic.com/cannabis-innovation-and-medical-research-balance/) Explore the relationship between legalization and innovation in cannabis research and development. [Read More](https://cedclinic.com/cannabis-innovation-and-medical-research-balance/) [State of Texas: Marijuana reclassification could expand medical research – KXAN Austin](https://cedclinic.com/marijuana-reclassification-medical-research-texas/) Learn how policy changes in Texas may influence the scope of [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) research. [Learn More](https://cedclinic.com/marijuana-reclassification-medical-research-texas/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).